{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T17:15:53Z","timestamp":1784740553385,"version":"3.55.0"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Allergy"],"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>Chronic rhinosinusitis with nasal polyps (CRSwNP) is an inflammatory disease of the nose and paranasal sinuses that significantly impactshealth-related quality of life. Nonsteroidal anti-inflammatory drug (NSAID) -exacerbated respiratory disease (N-ERD) affects approximately one fifth of CRSwNP patients. N-ERD and asthma increase the risk of uncontrolled CRSwNP as measured by frequent sinus surgeries and rescue treatment. Compared to non-N-ERD patients, those with N-ERD also have higher risk of asthma exacerbations, severe allergic reactions, and anosmia. Mepolizumab is a humanized monoclonal anti-IL-5 antibody shown to be effective in treating severe eosinophilic asthma and CRSwNP. While evidence suggests that mepolizumab alleviates respiratory symptoms in N-ERD patients, placebo-controlled studies remain limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>The aim of this prospective randomized, placebo-controlled, multicenter study is to investigate whether mepolizumab reduces polyp size, symptom scores, and exacerbations more than placebo during the 16-week treatment period in patients with uncontrolled CRSwNP, N-ERD and asthma. Additionally, we will examine the effect of mepolizumab on drug dosage and lung and nasal function and evaluate predictive biomarkers.<\/jats:p><jats:p>We will recruit 120 patients with N-ERD, nasal polyposis and asthma in three centers in Finland. Patients will be randomized into two 16-week treatment groups in 1:1 ratio (placebo or mepolizumab 100\u2005mg every 4 weeks). The study lasts for 6 months, including recruitment visit 2\u20134 weeks before randomization. Participants will attend 6 visits, during four of which they will receive a subcutaneous injection of the study product. At each visit, patient-reported outcome tests, clinical examination, airway function tests, and nasal, blood, urine, and stool samples will be conducted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>The efficacy of the 16-week anti-IL-5-treatment in this severe patient group will be analyzed, as well as possible predictive biomarkers.<\/jats:p><\/jats:sec><jats:sec><jats:title>Clinical Trial registration<\/jats:title><jats:p><jats:uri>ClinicalTrials.gov<\/jats:uri> ID NCT04823585. Registered on 28.3.2021.<\/jats:p><\/jats:sec>","DOI":"10.3389\/falgy.2025.1568081","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T07:36:14Z","timestamp":1742542574000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["Study protocol for a randomized double-blinded placebo-controlled trial on mepolizumab for patients with chronic rhinosinusitis with nasal polyps, NSAID exacerbated respiratory disease and asthma"],"prefix":"10.3389","volume":"6","author":[{"given":"Annina","family":"Lyly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sahlman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoliina","family":"Pajala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maija","family":"Salminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saara","family":"Sillanp\u00e4\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jura","family":"Numminen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanzeela","family":"Hanif","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anu","family":"Laulajainen-Hongisto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mika","family":"M\u00e4kel\u00e4","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Kauppi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iiris","family":"Kangasniemi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Lilja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sari","family":"Hammaren-Malmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula","family":"Virkkula","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanna","family":"Toppila-Salmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","article-title":"Epos 2020. European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"J Rhinol"},{"key":"B2","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1183\/13993003.00853-2015","article-title":"A summary of the new GINA strategy: a roadmap to asthma control","volume":"46","author":"Reddel","year":"2015","journal-title":"Eur Respir J"},{"key":"B3","doi-asserted-by":"publisher","first-page":"e4294","DOI":"10.1097\/MD.0000000000004294","article-title":"The link between chronic rhinosinusitis and asthma: a questionnaire-based study","volume":"95","author":"Huang","year":"2016","journal-title":"Medicine (Baltimore)"},{"key":"B4","doi-asserted-by":"publisher","first-page":"213","DOI":"10.4193\/Rhin19.468","article-title":"Direct and indirect costs of adult patients with chronic rhinosinusitis with nasal polyps","volume":"58","author":"Lourijsen","year":"2020","journal-title":"Rhinology"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1080\/02770903.2019.1633664","article-title":"The burden of adult asthma in Finland: impact of disease severity and eosinophil count on health care resource utilization","volume":"57","author":"Viinanen","year":"2019","journal-title":"J Asthma"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1061\u201370.e3","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps. Asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"50","DOI":"10.12932\/AP-310321-1102","article-title":"Eosinophilia, asthma, NERD and the use of oral corticosteroids predict uncontrolled chronic rhinosinusitis with nasal polyps after surgery","volume":"42","author":"Penttil\u00e4","year":"2024","journal-title":"Asian Pac J Allergy Immunol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"00576\u201302021","DOI":"10.1183\/23120541.00576-2021","article-title":"Type 2 inflammation in asthma and other airway diseases","volume":"8","author":"Maspero","year":"2022","journal-title":"ERJ Open Res"},{"key":"B9","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1038\/s41588-018-0314-6","article-title":"A loss-of-function variant in ALOX15 protects against nasal polyps and chronic rhinosinusitis","volume":"51","author":"Kristjansson","year":"2019","journal-title":"Nat Genet"},{"key":"B10","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.jaci.2021.06.019","article-title":"Immunology-based recommendations for available and upcoming biologics in aspirin-exacerbated respiratory disease","volume":"148","author":"Buchheit","year":"2021","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1016\/j.jaip.2021.12.030","article-title":"Controversies in allergy: aspirin desensitization or biologics for aspirin-exacerbated respiratory disease-how to choose","volume":"10","author":"Laidlaw","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2662","DOI":"10.1111\/all.16303","article-title":"Interleukin-5 as a pleiotropic cytokine orchestrating airway type 2 inflammation: effects on and beyond eosinophils","volume":"79","author":"Buchheit","year":"2024","journal-title":"Allergy"},{"key":"B13","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1186\/s12931-019-1134-7","article-title":"Mepolizumab reduces exacerbations in patients with severe eosinophilic asthma, irrespective of body weight\/body mass index: meta-analysis of MENSA and MUSCA","volume":"20","author":"Albers","year":"2019","journal-title":"Respir Res"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1016\/S2213-2600(21)00097-7","article-title":"Mepolizumab for chronic rhinosinusitis with nasal polyps (SYNAPSE): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Han","year":"2021","journal-title":"Lancet Respir Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3565","DOI":"10.1016\/j.jaip.2020.06.063","article-title":"High discontinuation rates of peroral ASA treatment for CRSwNP: a real-world multicenter study of 171 N-ERD patients","volume":"8","author":"Laulajainen-Hongisto","year":"2020","journal-title":"JACI IP"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhino50E2","article-title":"EPOS 2012: European position paper on rhinosinusitis and nasal polyps 2012. A summary for otorhinolaryngologists","volume":"50","author":"Fokkens","year":"2012","journal-title":"J Rhinol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1749-4486.2009.01995.x","article-title":"Psychometric validity of the 22-item sinonasal outcome test","volume":"34","author":"Hopkins","year":"2009","journal-title":"Clin Otolaryngol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1002\/lary.29888","article-title":"Estimating clinically meaningful change of efficacy outcomes in inadequately controlled CRSwNP","volume":"132","author":"Han","year":"2021","journal-title":"Laryngoscope"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomized, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.jaci.2021.08.030","article-title":"Efficacy and safety of benralizumab in chronic rhinosinusitis with nasal polyps: a randomized, placebo-controlled trial","volume":"149","author":"Bachert","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/alr.22900","article-title":"Outcomes of aspirin exacerbated respiratory disease patients treated with aspirin desensitization and biologics","volume":"12","author":"D\u2019Souza","year":"2022","journal-title":"Int Forum Allergy Rhinol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.anai.2022.01.043","article-title":"Aspirin desensitization and biologics in aspirin-exacerbated respiratory disease: efficacy, tolerability, and patient experience","volume":"128","author":"Mullur","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.jaip.2021.09.030","article-title":"Appraisal of the real-world effectiveness of biologic therapies in aspirin-exacerbated respiratory disease","volume":"10","author":"Wangberg","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B25","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/j.anai.2022.07.023","article-title":"Type 2 biologics reduce cumulative steroid exposure in aspirin-exacerbated respiratory disease","volume":"129","author":"Ghiasi","year":"2022","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1016\/j.jaci.2021.09.009","article-title":"Comparative efficacy and safety of monoclonal antibodies and aspirin desensitization for chronic rhinosinusitis with nasal polyposis: a systematic review and network meta-analysis","volume":"149","author":"Oykhman","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1016\/j.iac.2024.07.006","article-title":"Biologics in aspirin-exacerbated respiratory disease and allergic bronchopulmonary aspergillosis","volume":"44","author":"Huang","year":"2024","journal-title":"Immunol Allergy Clin North Am"}],"container-title":["Frontiers in Allergy"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1568081\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T07:36:16Z","timestamp":1742542576000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/falgy.2025.1568081\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":27,"alternative-id":["10.3389\/falgy.2025.1568081"],"URL":"https:\/\/doi.org\/10.3389\/falgy.2025.1568081","relation":{},"ISSN":["2673-6101"],"issn-type":[{"value":"2673-6101","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1568081"}}